Polyphor, a clinical stage biopharmaceutical company, focuses on the development of new antibiotics against Gram-negative bacteria with its Outer Membrane Protein Targeting Antibiotic (OMPTA) platform. Polyphor is also developing an immuno-oncology candidate to improve therapy outcomes in cancer.
Products, services, technology
Murepavadin: Outer Membrane Protein Targeting Antibiotic against Pseudomonas aeruginosa in Phase III,
Balixafortide: Antagonist of CXCR4 in Phase III for breast cancer,
POL6014 – Outlicensed to Santhera: Inhaled inhibitor of neutrophil elastase for treatment of severe lung diseases